Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs

Eue Keun Choi, Mark J. Shen, Shien-Fong Lin, Peng-Sheng Chen, Seil Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known to block pre-junctional β2-adrenoceptor responsible for norepinephrine release. Methods and results We implanted radiotransmitters to record stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA), and superior left ganglionated plexi nerve activity (SLGPNA) in 12 ambulatory dogs. Carvedilol (12.5 mg orally twice a day) was given for 7 days during sinus rhythm (n = 8). Four of the eight dogs and an additional four dogs were paced into persistent AF. Carvedilol reduced heart rate [from 103 b.p.m. (95% confidence interval (CI), 100-105) to 100 b.p.m. (95% CI, 98-102), P = 0.044], suppressed integrated nerve activities (Int-NAs, SGNA by 17%, VNA by 19%, and SLGPNA by 12%; all P < 0.05 vs. the baseline), and significantly reduced the incidence (from 8 ± 6 to 3 ± 3 episodes/day, P < 0.05) and total duration (from 68 ± 64 to 16 ± 21 s/day, P < 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly suppressed by carvedilol, but SGNA significantly increased by 16% after carvedilol withdrawal (P < 0.001). Conclusion Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.

Original languageEnglish
Pages (from-to)1083-1091
Number of pages9
JournalEuropace
Volume16
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Autonomic Pathways
Atrial Fibrillation
Dogs
Stellate Ganglion
Paroxysmal Tachycardia
Confidence Intervals
carvedilol
Adrenergic Receptors
Norepinephrine
Heart Rate

Keywords

  • Arrhythmia
  • Atrial fibrillation
  • Atrium
  • Autonomic nervous system
  • Carvedilol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Medicine(all)

Cite this

Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. / Choi, Eue Keun; Shen, Mark J.; Lin, Shien-Fong; Chen, Peng-Sheng; Oh, Seil.

In: Europace, Vol. 16, No. 7, 2014, p. 1083-1091.

Research output: Contribution to journalArticle

@article{c0847ae0a08b4c92af13f2f70abdaf37,
title = "Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs",
abstract = "Aims We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known to block pre-junctional β2-adrenoceptor responsible for norepinephrine release. Methods and results We implanted radiotransmitters to record stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA), and superior left ganglionated plexi nerve activity (SLGPNA) in 12 ambulatory dogs. Carvedilol (12.5 mg orally twice a day) was given for 7 days during sinus rhythm (n = 8). Four of the eight dogs and an additional four dogs were paced into persistent AF. Carvedilol reduced heart rate [from 103 b.p.m. (95{\%} confidence interval (CI), 100-105) to 100 b.p.m. (95{\%} CI, 98-102), P = 0.044], suppressed integrated nerve activities (Int-NAs, SGNA by 17{\%}, VNA by 19{\%}, and SLGPNA by 12{\%}; all P < 0.05 vs. the baseline), and significantly reduced the incidence (from 8 ± 6 to 3 ± 3 episodes/day, P < 0.05) and total duration (from 68 ± 64 to 16 ± 21 s/day, P < 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly suppressed by carvedilol, but SGNA significantly increased by 16{\%} after carvedilol withdrawal (P < 0.001). Conclusion Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.",
keywords = "Arrhythmia, Atrial fibrillation, Atrium, Autonomic nervous system, Carvedilol",
author = "Choi, {Eue Keun} and Shen, {Mark J.} and Shien-Fong Lin and Peng-Sheng Chen and Seil Oh",
year = "2014",
doi = "10.1093/europace/eut364",
language = "English",
volume = "16",
pages = "1083--1091",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs

AU - Choi, Eue Keun

AU - Shen, Mark J.

AU - Lin, Shien-Fong

AU - Chen, Peng-Sheng

AU - Oh, Seil

PY - 2014

Y1 - 2014

N2 - Aims We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known to block pre-junctional β2-adrenoceptor responsible for norepinephrine release. Methods and results We implanted radiotransmitters to record stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA), and superior left ganglionated plexi nerve activity (SLGPNA) in 12 ambulatory dogs. Carvedilol (12.5 mg orally twice a day) was given for 7 days during sinus rhythm (n = 8). Four of the eight dogs and an additional four dogs were paced into persistent AF. Carvedilol reduced heart rate [from 103 b.p.m. (95% confidence interval (CI), 100-105) to 100 b.p.m. (95% CI, 98-102), P = 0.044], suppressed integrated nerve activities (Int-NAs, SGNA by 17%, VNA by 19%, and SLGPNA by 12%; all P < 0.05 vs. the baseline), and significantly reduced the incidence (from 8 ± 6 to 3 ± 3 episodes/day, P < 0.05) and total duration (from 68 ± 64 to 16 ± 21 s/day, P < 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly suppressed by carvedilol, but SGNA significantly increased by 16% after carvedilol withdrawal (P < 0.001). Conclusion Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.

AB - Aims We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known to block pre-junctional β2-adrenoceptor responsible for norepinephrine release. Methods and results We implanted radiotransmitters to record stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA), and superior left ganglionated plexi nerve activity (SLGPNA) in 12 ambulatory dogs. Carvedilol (12.5 mg orally twice a day) was given for 7 days during sinus rhythm (n = 8). Four of the eight dogs and an additional four dogs were paced into persistent AF. Carvedilol reduced heart rate [from 103 b.p.m. (95% confidence interval (CI), 100-105) to 100 b.p.m. (95% CI, 98-102), P = 0.044], suppressed integrated nerve activities (Int-NAs, SGNA by 17%, VNA by 19%, and SLGPNA by 12%; all P < 0.05 vs. the baseline), and significantly reduced the incidence (from 8 ± 6 to 3 ± 3 episodes/day, P < 0.05) and total duration (from 68 ± 64 to 16 ± 21 s/day, P < 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly suppressed by carvedilol, but SGNA significantly increased by 16% after carvedilol withdrawal (P < 0.001). Conclusion Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.

KW - Arrhythmia

KW - Atrial fibrillation

KW - Atrium

KW - Autonomic nervous system

KW - Carvedilol

UR - http://www.scopus.com/inward/record.url?scp=84903997241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903997241&partnerID=8YFLogxK

U2 - 10.1093/europace/eut364

DO - 10.1093/europace/eut364

M3 - Article

C2 - 24469435

AN - SCOPUS:84903997241

VL - 16

SP - 1083

EP - 1091

JO - Europace

JF - Europace

SN - 1099-5129

IS - 7

ER -